Keyword: PRA Health Sciences
Takeda's quarterly margin hits 32.4%; the FDA slaps a Dr. Reddy's API plant with a Form 483; Strides Pharma enters China through a joint venture.
As the head of Takeda’s R&D transformation office and R&D communications, Dominika Kovacs has been instrumental in Takeda’s innovative clinical development partnership with PRA Health Sciences.
The FDA served a Mylan plant with a warning letter, Takeda inked a microbiome GI deal with NuBiyota and China works on new trial data fabrication policies.
PRA and Takeda are building a Japan JV, Sun's quarterly profits dropped, ASLAN posted positive top-line phase 2 data for varlitinib.